Use of Intravascular Micro-Axial Left Ventricular Assist Devices as a Bridging Strategy for Cardiogenic Shock:...

Area of Science:

• Cardiology
• Medical Devices
• Critical Care Medicine

Background:

• Cardiogenic shock (CS) presents a critical challenge in cardiovascular care.
• Intravascular micro-axial left ventricular assist devices (M-LVADs) offer a potential therapeutic option for CS patients.
• M-LVADs can serve as a bridge to recovery or definitive treatment.

Purpose of the Study:

• To evaluate the mid-term outcomes of M-LVAD implantation in patients with cardiogenic shock.
• To identify predictors of early and late mortality in CS patients treated with M-LVADs.
• To compare survival rates across different indications for M-LVAD use.

Main Methods:

• A retrospective analysis of 107 CS patients implanted with M-LVADs from January 2020 to May 2024.
• Patients were categorized into groups based on the intended therapy: bridge to transplant, bridge to durable LVAD, and postcardiotomy CS (PCCS).
• Multivariable logistic and Cox regression models were employed to identify mortality predictors, with statistical significance set at p < 0.05.

Main Results:

• Complications included device malfunction (6%), GI bleed (9%), long-term dialysis (21%), axillary hematoma (10%), HIT (4%), and stroke (11%).
• Early hospital mortality was 12% (13/107), significantly higher in the PCCS group (p=0.02).
• At 4.5 years, actuarial survival was 90.7% (transplant), 79.2% (durable LVAD), and 62.8% (PCCS) (p=0.01), with M-LVAD category and long-term dialysis predicting mortality.

Conclusions:

• M-LVADs demonstrate favorable mid-term survival as a bridge to transplant or durable LVADs in CS patients.
• Reasonable survival is achievable with M-LVADs for postcardiotomy recovery, associated with reduced ECMO use and earlier rehabilitation.
• M-LVAD category and need for long-term dialysis are significant predictors of mortality in this cohort.